[go: up one dir, main page]

CO2018007239A2 - Reguladores de ctfr y métodos de uso de los mismos - Google Patents

Reguladores de ctfr y métodos de uso de los mismos

Info

Publication number
CO2018007239A2
CO2018007239A2 CONC2018/0007239A CO2018007239A CO2018007239A2 CO 2018007239 A2 CO2018007239 A2 CO 2018007239A2 CO 2018007239 A CO2018007239 A CO 2018007239A CO 2018007239 A2 CO2018007239 A2 CO 2018007239A2
Authority
CO
Colombia
Prior art keywords
methods
ctfr
regulators
disorders
diseases
Prior art date
Application number
CONC2018/0007239A
Other languages
English (en)
Inventor
Marc H Levin
Onur Cil
Alan Verkman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CO2018007239A2 publication Critical patent/CO2018007239A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Prostheses (AREA)

Abstract

En el presente documento se proporcionan compuestos que activan el CFTR y métodos para tratar el estreñimiento, los trastornos del ojo seco u otras enfermedades y trastornos.
CONC2018/0007239A 2015-12-24 2018-07-11 Reguladores de ctfr y métodos de uso de los mismos CO2018007239A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387591P 2015-12-24 2015-12-24
PCT/US2016/068561 WO2017112947A1 (en) 2015-12-24 2016-12-23 Cftr regulators and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2018007239A2 true CO2018007239A2 (es) 2018-07-19

Family

ID=59091233

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007239A CO2018007239A2 (es) 2015-12-24 2018-07-11 Reguladores de ctfr y métodos de uso de los mismos

Country Status (16)

Country Link
US (2) US20190031630A1 (es)
EP (1) EP3394083B9 (es)
JP (1) JP6894902B2 (es)
KR (1) KR102723194B1 (es)
CN (1) CN108699107B (es)
AU (2) AU2016377782B2 (es)
BR (1) BR112018012927A2 (es)
CL (1) CL2018001714A1 (es)
CO (1) CO2018007239A2 (es)
ES (1) ES2901002T3 (es)
IL (2) IL299924B2 (es)
PL (1) PL3394083T3 (es)
PT (1) PT3394083T (es)
RU (1) RU2742934C2 (es)
WO (1) WO2017112947A1 (es)
ZA (1) ZA201804228B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6938510B2 (ja) 2015-12-24 2021-09-22 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｃｆｔｒ制御因子及びこの使用方法
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
AU2018321926B2 (en) * 2017-08-24 2023-09-21 The Regents Of The University Of California Ocular pharmaceutical compositions
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
US20220071549A1 (en) * 2020-09-08 2022-03-10 The Regents Of The University Of California Apparatus, systems and methods of use for ocular surface potential difference measurement
WO2022084741A1 (en) 2020-10-23 2022-04-28 Ildong Pharmaceutical Co., Ltd. Cftr modulator compounds, compositions, and uses thereof
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042298A (ko) 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논
NZ538809A (en) * 2002-09-30 2008-06-30 Univ California Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
AU2005210474B2 (en) * 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20090105240A1 (en) * 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
WO2009109258A1 (en) 2008-03-05 2009-09-11 Merck Patent Gmbh Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
WO2010048564A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2012092471A2 (en) * 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
CA2942386A1 (en) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015196071A1 (en) * 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity

Also Published As

Publication number Publication date
US20190031630A1 (en) 2019-01-31
RU2742934C2 (ru) 2021-02-11
RU2018126959A3 (es) 2020-08-20
RU2018126959A (ru) 2020-01-24
IL260210B2 (en) 2023-06-01
WO2017112947A1 (en) 2017-06-29
ES2901002T3 (es) 2022-03-21
ES2901002T9 (es) 2022-06-20
JP2018538354A (ja) 2018-12-27
EP3394083A1 (en) 2018-10-31
EP3394083B9 (en) 2022-04-27
KR20180101415A (ko) 2018-09-12
NZ743720A (en) 2024-08-30
EP3394083A4 (en) 2019-09-04
BR112018012927A2 (en) 2018-12-11
IL299924B1 (en) 2024-09-01
IL260210A (en) 2018-07-31
IL299924B2 (en) 2025-01-01
AU2016377782A1 (en) 2018-07-12
JP6894902B2 (ja) 2021-06-30
US20200140402A1 (en) 2020-05-07
CN108699107A (zh) 2018-10-23
AU2021257948B2 (en) 2023-11-30
PL3394083T3 (pl) 2022-01-17
CN108699107B (zh) 2022-05-10
ZA201804228B (en) 2020-09-30
EP3394083B1 (en) 2021-09-01
IL299924A (en) 2023-03-01
CL2018001714A1 (es) 2018-10-26
AU2016377782B2 (en) 2021-07-29
AU2021257948A1 (en) 2021-11-25
US11192869B2 (en) 2021-12-07
KR102723194B1 (ko) 2024-10-28
PT3394083T (pt) 2021-12-07
CA3009531A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CO2018007239A2 (es) Reguladores de ctfr y métodos de uso de los mismos
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
CL2017003103A1 (es) Compuestos de heteroarilo para la inhibición de cinasa
MX389460B (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
CL2017001124A1 (es) Agentes inmunomoduladores
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MX2018004290A (es) Compuestos, composiciones y metodos para modular el regulador de la conductancia transmembrana de la fibrosis quistica.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
CR20150316A (es) Compuestos y sus métodos de empleo
CO2018007237A2 (es) Reguladores del cftr y métodos para su uso
MX2017014375A (es) Moduladores del ccr2.
UY36716A (es) Moduladores de receptores nucleares
BR112018008960A8 (pt) estrutura de relatório de formação de feixe
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
MX2018010993A (es) Derivados de icariina e icaritina.